title: Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
authors: Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA. reeder.craig@mayo.edu.
authors: Craig B
authors: CB
authors: Reeder
authors: Donna E
authors: DE
authors: Reece
authors: Vishal
authors: V
authors: Kukreti
authors: Joseph R
authors: JR
authors: Mikhael
authors: Christine
authors: C
authors: Chen
authors: Suzanne
authors: S
authors: Trudel
authors: Kristina
authors: K
authors: Laumann
authors: Harjot
authors: H
authors: Vohra
authors: Rafael
authors: R
authors: Fonseca
authors: P Leif
authors: PL
authors: Bergsagel
authors: Jose F
authors: JF
authors: Leis
authors: Rodger
authors: R
authors: Tiedemann
authors: A Keith
authors: AK
authors: Stewart
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide
keywords: bortezomib; cyclophosphamide; myeloma; survival